MS cannabis treatment doubt13th December 2012
Doubts have been raised over the use of cannabis extract in the treatment of multiple sclerosis.
A review of evidence in the December issue of Drug and Therapeutics Bulletin (DTB), published by BMJ Journals, on the first licensed preparation Sativex suggested it had limitations which made it difficult to identify the place of the product in clinical practice. However GW Pharmaceuticals, which makes of the drug, indicated the comments gave a misleading view and that the review writers appeared to have misunderstood important elements of trials.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: MS cannabis treatment doubt
Author: Mark Nicholls
Article Id: 23368
Date Added: 13th Dec 2012